IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug tested for rare kidney conditions
Disease control CompletedThis early-stage study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with rare kidney diseases (C3G and IgAN). The goal was to see how the body processes the drug and determine safe dose levels for future resea…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New drug tested to protect kidneys from scarring disease
Disease control CompletedThis study tested whether adding the drug atrasentan helps control IgA nephropathy, a kidney disease that causes scarring, in patients already taking standard protective medications. Fifty-four adults with the disease tried atrasentan and a placebo in different orders to see whic…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New drug shows promise in slowing kidney disease progression
Disease control CompletedThis large, completed Phase 3 trial tested whether the drug iptacopan (LNP023) could help control IgA nephropathy, a serious kidney disease. It involved 518 adults with the condition who were already on standard care. The main goals were to see if the drug could reduce harmful pr…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New pill tested to protect kidneys from silent disease
Disease control CompletedThis study tested whether a new capsule called HR19042 could safely reduce protein loss in the urine for people with IgA nephropathy, a kidney disease. It compared the capsule to a placebo (dummy pill) in 316 adults with confirmed disease. The main goal was to see which dose work…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Kidney biopsy guides fight against silent kidney killer
Disease control CompletedThis study tested whether adding steroid therapy to standard kidney-protecting medications works better for IgA nephropathy patients with severe kidney damage seen on biopsy. Researchers compared two treatment approaches over two years in 62 adults with this autoimmune kidney dis…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC